Cargando…
Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
BACKGROUND: Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured, and median survival times are generally in the 12-month range. Novel approaches to treatment are unquestionably needed. The Inhibitor of Apoptosis Protein (IAP) family me...
Autores principales: | Thamm, Douglas H., Joseph, Jenette K., Rose, Barbara J., Meuten, Travis K., Weishaar, Kristen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092583/ https://www.ncbi.nlm.nih.gov/pubmed/32209084 http://dx.doi.org/10.1186/s12917-020-02317-3 |
Ejemplares similares
-
Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma
por: Siewert, Jacob M., et al.
Publicado: (2023) -
DNA Repair Deficiency as a Susceptibility Marker for Spontaneous Lymphoma in Golden Retriever Dogs: A Case-Control Study
por: Thamm, Douglas H., et al.
Publicado: (2013) -
Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy
por: Heishima, Kazuki, et al.
Publicado: (2019) -
In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
por: Pyuen, Alex A., et al.
Publicado: (2018) -
Recurrence of benign paroxysmal positional vertigo: experience in 3042 patients
por: Teggi, Roberto, et al.
Publicado: (2021)